French biotech company Deinove (Euronext Growth Paris: ALDEI) has signed a license option agreement with British firm Redx Pharma (AIM: REDX) for the acquisition of its first-in-class anti-infective program, novel bacterial topoisomerase inhibitor (NBTI).
Although no financial terms of the deal were provided, it is good news for Redx, which only last November exited administration as a going concern. However, the company’s shares dipped 2.2% to 11.00 pence in mid-morning trading.
Redx announced in March 2017 that it would concentrate on the development of its cancer and fibrosis products and would look to partner its anti-infective programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze